当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2019年, 第19卷, 第2期, 第121-124页
标题:
用于治疗前列腺癌的卡巴他赛递药系统研究进展
DOI:
10.5428/pcar20190211
作者:
1. 万众1(1.海军军医大学长征医院泌尿外科 上海 200003 smmuwz@126.com)
2. 孙治国2(2.海军军医大学药学院药剂学教研室 上海 200433 )
3. 鲁莹2(2.海军军医大学药学院药剂学教研室 上海 200433 )
4. 王林辉1(1.海军军医大学长征医院泌尿外科 上海 200003 wanglinhuicz@163.com)
摘要:
摘要  卡巴他赛是一种新型紫杉烷类抗肿瘤药物,对于多西他赛治疗无效的、激素难治性、转移性前列腺癌患者效果显著。虽然作为临床二线用药,但由于卡巴他赛对P-糖蛋白的低黏附性以及良好的药动学特性,使其具有较大的应用潜力,近年来越来越受到研究者们的关注。本文结合国内外研究进展,以卡巴他赛的药理作用、不良反应为出发点,对其用于前列腺癌治疗的递药系统研究进行综述。
欢迎阅读《药学服务与研究》!您是该文第 222 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 万众1,孙治国2,鲁莹2,王林辉1. 用于治疗前列腺癌的卡巴他赛递药系统研究进展[J]. 药学服务与研究. 2019; 19(2): 121-124.
英文著录格式 WAN Zhong1,SUN Zhiguo2,LU Ying2,WANG Linhui1. Research advances in drug delivery system of cabazitaxel for treatment of patients with prostate cancer[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(2): 121-124.
参考文献:
1. Siegel R L,Miller K D,Jemal A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.
2. 叶定伟,朱耀.中国前列腺癌的流行病学概述和启示[J].中华外科杂志,2015,53(4):249-252.
3. 董隽.激素难治性前列腺癌对多西他赛耐药机制的研究进展[J].中华泌尿外科杂志,2011,32(2):138-140.
4. 中国医促会泌尿健康促进分会,中国研究型医院协会泌尿外科分会.前列腺癌化疗安全共识[J].现代泌尿外科杂志,2018,23(2):85-92.
5. 周爱萍,房虹,李长岭,等.去势抗拒前列腺癌治疗新药卡巴他赛[J].中国新药杂志,2013,22(19):2229-2231.
6. 郝斌,马志方.去势抵抗性前列腺癌化疗及其新进展[J].临床泌尿外科杂志,2015,30(1):83-87.
7. ZHUANG Bo,DU Liang,XU Hongxia,et al.Self-assembled micelle loading cabazitaxel for therapy of lung cancer[J].Int J Pharm,2016,499(1-2):146-155.
8. Clèment-Zhao A,Auvray M,Aboudagga H,et al.Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer[J].BJU Int,2018,121(2):203-208.
9. Oudard S,Fizazi K,Sengelv L,et al.Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer:a randomized phase Ⅲ trial-FIRSTANA[J].J Clin Oncol,2017,35(28):3189-3197.
10. 于小杰,伍一波,毛静,等.聚乙二醇-b-聚乳酸末端官能团的合成及在卡巴他赛载药体系中的应用[J].高分子材料科学与工程,2018,34(6):42-48.
11. HAN Xiaoxiong,CHEN Dan,SUN Jing,et al.A novel cabazitaxel-loaded polymeric micelle system with superior in vitro stability and long blood circulation time[J].J Biomater Sci Polym Ed,2016,27(7):626-642.
12. Aydin O,Youssef I,Yuksel Durmaz Y,et al.Formulation of acid-sensitive micelles for delivery of cabazitaxel into prostate cancer cells[J].Mol Pharm,2016,13(4):1413-1429.
13. Perez-Lopez R,Lorente D,Blackledge M D,et al.Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer[J].Radiology,2016,280(1):151-160.
14. Gdowski A S,Ranjan A,Sarker M R,et al.Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesion and pain[J].Nanomedicine(Lond),2017,12(17):2083-2095.
15. 张淼,何瑶.卡巴他赛纳米混悬剂的制备与质量评价[J].中国药师,2018,21(7):1167-1171.
16. Bteich J,McManus S A,Ernsting M J,et al.Using flash nanoprecipitation to produce highly potent and stable cellax nanoparticles from amphiphilic polymers derived from carboxymethyl cellulose,polyethylene glycol and cabazitaxel[J]. Mol Pharm,2017,14(11):3998-4007.
17. LIU Yang,XIE Bin,LI Lin,et al.PEGylated lipid microspheres loaded with cabazitaxel for intravenous administration: stability,bioavailability,antitumor efficacy and toxicity[J]. Drug Deliv Transl Res,2018,8(5):1365-1379.
18. CHEN Weijun,GUO Miao,WANG Shuli.Anti prostate cancer using PEGylated bombesin containing,cabazitaxel loading nano-sized drug delivery system[J].Drug Dev Ind Pharm,2016,42(12):1968-1976.
19. 张海军,王英杰,刘留成. 卡巴他赛脂质体制备、质量控制及稳定性研究[J].中西医结合心脑血管病杂志,2017,15(7):805-808.
20. 张丽,李亚平,陈伶俐.卡巴他赛脂质体的制备及其大鼠药动学[J]. 中国医药工业杂志,2017,48(6):874-878.
21. 王梦迪,何广卫.靶向递药系统白蛋白纳米粒的研究进展[J].安徽医药,2013,17(10):1649-1651.
22. QU Na,Lee R J,SUN Yating,et al.Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer[J].Int J Nanomed,2016,11:3451-3459.
23. Qu N,Sun Y,Xie J,et al.Preparation and evaluation of in vitro self-assembling HSA nanoparticles for cabazitaxel[J].Anticancer Agents Med Chem,2017,17(2):294-300.